Rico, It appears that a rotation out of biotech's is happening. Add to your position during weakness and by end of year Tedizolid will be approved for MRSA skin infections. This chemistry is more potent then earlier compound on the market. This is a small company and most of their resources are going into writing and preparing the upcoming NDA. Once approved Trius will release data by increasing dosage and dosing intervals which will prove that TED is more efficaceous than Linezolid. In the infectious disease community, once an antibiotic proves to be more efficaceous than the standard-of-care, 95% of practioners will place their its. on it. Pfizer knows this. Once that happens Trius will be bought out at multiples of where it is trading today.